{"filing":{"accession_number":"0001193125-26-356168","cik":"0001719714","ticker":"MREO","company_name":"Mereo BioPharma Group plc","form":"8-K","filing_date":"2026-08-19","report_date":"2026-08-18","primary_document":"mreo-20260217.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1719714/000119312526356168/mreo-20260217.htm"},"events":[{"id":28397,"run_id":25973,"accession_number":"0001193125-26-356168","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Mereo received a second notice from Nasdaq on August 18, 2026, indicating failure to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). While the company has been granted an additional 180-day compliance period until February 16, 2027, the disclosure explicitly states that failure to regain compliance will result in delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting the company's continued listing status and investor confidence.","company_name":"Mereo BioPharma Group plc","ticker":"MREO","filing_date":"2026-08-19","form":"8-K","submitted_at":null,"items":[{"id":30330,"accession_number":"0001193125-26-356168","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Mereo received a second notice from Nasdaq on August 18, 2026, indicating failure to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). While the company has been granted an additional 180-day compliance period until February 16, 2027, the disclosure explicitly states that failure to regain compliance will result in delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting the company's continued listing status and investor confidence.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T11:53:36.467868+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30330,"accession_number":"0001193125-26-356168","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Mereo received a second notice from Nasdaq on August 18, 2026, indicating failure to maintain the minimum $1.00 bid price requirement under Nasdaq Listing Rule 5550(a)(2). While the company has been granted an additional 180-day compliance period until February 16, 2027, the disclosure explicitly states that failure to regain compliance will result in delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting the company's continued listing status and investor confidence.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T11:53:36.467868+00:00","company_name":"Mereo BioPharma Group plc","ticker":"MREO","filing_date":"2026-08-19"}]}